Your browser is no longer supported. Please, upgrade your browser.
Settings
CLRB Cellectar Biosciences, Inc. daily Stock Chart
CLRB [NASD]
Cellectar Biosciences, Inc.
Index- P/E1.17 EPS (ttm)1.10 Insider Own2.90% Shs Outstand9.92M Perf Week2.40%
Market Cap12.70M Forward P/E- EPS next Y-0.86 Insider Trans115.87% Shs Float8.52M Perf Month-3.03%
Income-2.60M PEG- EPS next Q-0.22 Inst Own15.50% Short Float5.71% Perf Quarter-46.44%
Sales- P/S- EPS this Y59.90% Inst Trans77.43% Short Ratio1.36 Perf Half Y-56.31%
Book/sh1.44 P/B0.89 EPS next Y-7.50% ROA-31.30% Target Price5.07 Perf Year-74.40%
Cash/sh0.56 P/C2.27 EPS next 5Y- ROE-48.60% 52W Range1.00 - 7.40 Perf YTD4.92%
Dividend- P/FCF- EPS past 5Y37.10% ROI- 52W High-82.70% Beta0.55
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low28.00% ATR0.13
Employees19 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)44.84 Volatility11.24% 10.21%
OptionableNo Debt/Eq0.03 EPS Q/Q82.70% Profit Margin- Rel Volume1.21 Prev Close1.32
ShortableYes LT Debt/Eq0.00 EarningsFeb 09 BMO Payout0.00% Avg Volume357.34K Price1.28
Recom1.00 SMA200.55% SMA50-17.39% SMA200-46.82% Volume426,500 Change-3.03%
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Jan-05-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at the 9th Annual Biotech Showcase GlobeNewswire
Dec-21-16 06:59AM  Coverage initiated on Cellectar Biosciences by Ladenburg Thalmann
Dec-20-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs GlobeNewswire
Dec-19-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Other Events -6.20%
Dec-14-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -6.06%
08:30AM  Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types GlobeNewswire
Dec-12-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035 GlobeNewswire
Dec-09-16 04:07PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-06-16 04:08PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology GlobeNewswire
Dec-01-16 04:09PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies GlobeNewswire
Nov-30-16 04:33PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, -5.16%
01:04PM  CELLECTAR BIOSCIENCES, INC. Financials
Nov-29-16 06:40PM  Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option GlobeNewswire
Nov-28-16 04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production GlobeNewswire
Nov-23-16 11:47AM  Cellectar Biosciences (CLRB), Juno Therapeutics (JUNO), Newmont Mining (NEM) and More: What is Going on With These Falling Stocks? at Insider Monkey -31.02%
08:30AM  Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering GlobeNewswire
Nov-17-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:11AM  Movers In Biotech: Cellectar Biosciences Inc (CLRB) And The Medicines Company (MDCO) at Insider Monkey
08:00AM  Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors GlobeNewswire
Nov-16-16 09:00AM  SeeThruEquity Issues Update on Cellectar Biosciences, Inc. (NASDAQ:CLRB) Accesswire +12.77%
Nov-15-16 10:00AM  Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial GlobeNewswire +26.34%
Nov-11-16 07:05PM  Cellectar Biosciences Inc (CLRB) Is Oversold And Ready To Bounce Higher at Insider Monkey +7.34%
01:50PM  UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results GlobeNewswire
Nov-10-16 04:32PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:15PM  Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results GlobeNewswire
04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 04:07PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Host Conference Call on November 11 to Report Third Quarter 2016 Financial Results and Corporate Performance GlobeNewswire
Oct-31-16 04:16PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +6.32%
09:45AM  Cellectar Biosciences Announces Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma and Other Hematologic Malignancies GlobeNewswire
Oct-24-16 05:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -10.29%
08:30AM  Cellectar Biosciences Announces Data on CLR 131 Accepted For Poster Presentation at the 58th Annual American Society of Hematology Meeting & Exposition GlobeNewswire
Oct-13-16 08:30AM  Cellectar Biosciences To Present at BIO Investor Forum GlobeNewswire
Oct-11-16 08:30AM  Cellectar Biosciences To Present at SeeThru Equity and Dawson James Investor Conferences GlobeNewswire
Oct-06-16 04:12PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma GlobeNewswire
Oct-05-16 06:08AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-04-16 08:30AM  Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603 GlobeNewswire
Sep-29-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma GlobeNewswire
Sep-21-16 08:30AM  Cellectar Biosciences To Present at OktoberINVESTfest GlobeNewswire
Sep-19-16 08:30AM  Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference GlobeNewswire
Sep-12-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant GlobeNewswire
Sep-06-16 08:30AM  Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +6.94%
Aug-18-16 09:00AM  SeeThruEquity Issues Update on Cellectar Biosciences, Inc. (Nasdaq: CLRB) Accesswire
Aug-17-16 11:06AM  Edited Transcript of CLRB earnings conference call or presentation 15-Aug-16 12:30pm GMT
Aug-12-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +10.07%
03:25PM  UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results GlobeNewswire
Aug-11-16 04:45PM  Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results GlobeNewswire
04:06PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
07:50AM  Medical Product Stock Earnings Coming Up: IMMY, OMCM, CLRB
Aug-09-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aug-08-16 08:30AM  Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance GlobeNewswire
Aug-03-16 08:00AM  Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study GlobeNewswire +6.69%
Jul-27-16 04:04PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant +8.24%
Jul-21-16 08:30AM  StockNewsNow.com Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development PR Newswire
Jul-20-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
08:30AM  Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations GlobeNewswire
Jul-18-16 09:00AM  SeeThruEquity Initiates Coverage on Cellectar Biosciences, Inc. (NASDAQ: CLRB) with a Price Target of $7.44 Accesswire -10.24%
Jul-14-16 12:00AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements a
Jun-30-16 04:30PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-23-16 04:10PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer GlobeNewswire
Jun-17-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jun-15-16 12:09PM  Why Perrigo Company & Four Other Stocks Are Making Headlines on Wednesday at Insider Monkey +15.76%
11:05AM  6 Biopharma Movers Making a Run on Wednesday at 24/7 Wall St.
09:16AM  Cellectar's stock soars after positive results of a study of its tumor treatment at MarketWatch
08:30AM  Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel GlobeNewswire
Jun-08-16 05:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jun-03-16 09:17AM  These Stocks Are Making Big Moves -6.43%
Jun-02-16 04:08PM  6 Biotechs Seriously on the Move at 24/7 Wall St. +23.49%
08:30AM  Cellectar Biosciences to Present at the LD Micro Invitational Accesswire
May-31-16 08:30AM  Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform GlobeNewswire +7.62%
May-26-16 06:09AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -12.68%
May-25-16 06:39PM  A test of conscience at a trading firm +12.70%
11:45AM  Cellectar Wins Big on New Patent
08:30AM  Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel GlobeNewswire
May-24-16 08:30AM  Cellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference GlobeNewswire -22.60%
May-23-16 12:15PM  Heres Why Traders Are Piling Into These Five Stocks at Insider Monkey +17.97%
11:53AM  A favorite trade of active successful traders
08:30AM  Cellectar Biosciences to Present at the 2016 Marcum MicroCap Conference GlobeNewswire
06:07AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
May-20-16 05:58PM  A note from the prop desk +228.57%
05:30PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
01:09PM  Cellectar Biosciences Jumps 200% After Geting Patent Identification Numbers For Cancer Targeting Drug Vehicles
08:30AM  Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO GlobeNewswire
May-19-16 05:23PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi -8.70%
May-16-16 04:13PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:05PM  Cellectar Biosciences Satisfies All Nasdaq Listing Criteria GlobeNewswire
May-12-16 04:15PM  Cellectar Biosciences Announces First Quarter 2016 Financial Results GlobeNewswire
11:14AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
May-04-16 08:30AM  Cellectar Biosciences to Host Conference Call on May 12, 2016 to Report First Quarter 2016 Financial Results and Provide a Corporate Performance Update GlobeNewswire
May-03-16 08:52AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEIS JOHNDirectorNov 29Buy1.49333,333496,666631,317Nov 30 06:59 PM